Yoshiyuki Hamamoto

机构：Kansai Electric Power (Japan), Kansai Electric Power Hospital · ORCID：0000-0002-1938-7394

发表论文 140 篇 · 总被引 2521 次 · h-index 25

代表论文

• Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial (2020 · The Lancet Diabetes & Endocrinology · 被引 230)
• Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis (2022 · Diabetes Care · 被引 215)
• Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (2023 · The Lancet Diabetes & Endocrinology · 被引 122)
• Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (2023 · Annals of Internal Medicine · 被引 102)
• Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (2023 · The Lancet Diabetes & Endocrinology · 被引 98)
• Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study (2021 · Journal of Diabetes Investigation · 被引 42)